BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled « Landscape in Gene Therapy Companies »
In this 800-pages report, a must-have read one, you will find
-More than 230 closely scrutinized companies
-More than 600 products identified including more than 200 products at the clinical stage
-More than 300 VC or investors mentioned
-Mor than 200 pathologies referred
-A detailed Overview of Companies involved in AAV-based gene therapy, LV-based Gene Therapy, Gene Therapy, CDMO (Contracts, Manufacturing Organisation) and a Miscellaneous section including Hubs and Non Viral Gene Transfer)
CAR-T strategies will be dealt separately in the updated edition of our Briefing on CAR-T clinical trials. The 2019 edition will be published next November
For further information, alb@biopharmanalyses.fr or olivier@octopusyx.fr
Please visit http://biopharmanalyses.fr/product/landscape-in-gene-therapy-companies-sep-2019/